Conference Coverage

Metformin appears to be associated with reduced colorectal cancer risk


 

AT DDW 2013

ORLANDO – Metformin may be associated with a reduced risk of colorectal cancer in patients with type 2 diabetes, according to a meta-analysis that included mostly observational studies.

Sulfonylurea and insulin were not associated with a reduced risk and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week.

Dr. Siddharth Singh

CRC incidence was reduced by 10% among patients who were on metformin (n = 10 studies; adjusted odds ratio [AOR], 0.90; 95% confidence interval, 0.82-0.99; P = .02). The results were stable when the analysis was restricted to high-quality observational studies (n = 7 studies; AOR, 0.88; 95% CI, 0.79-0.98).

CRC risk was higher in patients on a sulfonylurea (n = 8 studies; AOR 1.12; 95% CI 0.99-1.26; P = .07) or on insulin (n = 10 studies; AOR, 1.25; 95% CI, 0.91-1.71; P = 0.17). Neither result was statistically significant, however.

Dr. Singh said that the findings warrant prospective cohort studies or randomized controlled trials of the chemopreventive effect of metformin in adults with type 2 diabetes.

Diabetes is an established risk factor for colorectal cancer, and preclinical and observational studies have shown that antidiabetes drugs may affect CRC risk. The relative affect of various antidiabetes drugs on CRC risk is unclear, said Dr. Singh of the Mayo Clinic in Rochester, Minn.

Dr. Singh and his colleagues conducted a systematic review and meta-analysis of 15 studies evaluating the effects of metformin, TZDs, sulfonylureas, and insulin on colorectal cancer risk. There was considerable heterogeneity across the studies, which may be explained by study design, location, and whether the study accounted for the effects of other antidiabetic drugs, Dr. Singh said.

Five case-control studies, eight cohort studies, and two randomized controlled trials with a total of nearly 14,000 CRC cases in 841,000 diabetes patients were included in the meta-analysis.

TZD was not associated with CRC risk (n = 6 studies; AOR, 0.95; 95% CI, 0.87-1.03; P = .24).

One of the main limitations of the unpublished study was that the significant results were seen only in observational studies and not in post-hoc analysis of the randomized controlled trials. Also, there are residual confounding factors, including failure to adjust for obesity, and confounding by indication and severity of diabetes, Dr. Singh said.

"Before we take part in any proactive treatment regimen, we have to have well-designed, randomized controlled trials," said Dr. N. Jewel Samadder, assistant professor of medicine at the University of Utah, Salt Lake City. "However, the observational studies, and the meta-analysis that [follow], are certainly hypothesis driving. Diabetes itself is a risk factor [for CRC], and some of the medications may alter that risk," said Dr. Samadder, who was not involved in the study.

Dr. Singh had no disclosures. Dr. Samadder has received speaking and teaching honoraria from Cook.

nmiller@frontlinemedcom.com

On Twitter @NaseemSMiller

Recommended Reading

One in five U.S. adults meets exercise guidelines
MDedge Endocrinology
Diabetes 'cure' holds up 6 years after bariatric surgery
MDedge Endocrinology
Mediterranean diet: No glycemic advantage, but sound dietary approach
MDedge Endocrinology
Hypoglycemia associated with daily variation in blood glucose
MDedge Endocrinology
Newcomer canagliflozin improves beta-cell function in type 2 diabetes
MDedge Endocrinology
AACE president shares advice with endocrinologists
MDedge Endocrinology
Insulin resistance may predict ventilator-associated pneumonia
MDedge Endocrinology
DEA scheduling brings weight-loss drug closer to market
MDedge Endocrinology
Fewer nocturnal hypoglycemia episodes with insulin degludec
MDedge Endocrinology
Type 2 diabetics often harbor undiagnosed heart failure
MDedge Endocrinology